OncoMatch/Clinical Trials/Sotorasib
Sotorasib (AMG 510) Clinical Trials
Sotorasib (Lumakras, AMG 510) was the first KRAS G12C inhibitor to receive FDA approval, approved in 2021 for previously treated KRAS G12C–mutant advanced NSCLC based on the CodeBreak 100 trial. The CodeBreak 200 Phase 3 trial subsequently compared sotorasib to docetaxel in second-line KRAS G12C–mutant NSCLC. Sotorasib combined with panitumumab received FDA accelerated approval for KRAS G12C–mutant colorectal cancer in late 2024 (CodeBreak 300), addressing the limited single-agent activity driven by EGFR feedback reactivation in that setting. Active trials continue to evaluate sotorasib combinations with chemotherapy and immunotherapy across NSCLC and other KRAS G12C–mutant tumor types. Eligibility requires confirmed KRAS G12C mutation; colorectal trials typically specify prior oxaliplatin- and irinotecan-based therapy.
Check your eligibilityRecruiting Sotorasib trials
Ranked by phase and US site count. Filter by your biomarker profile →
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Amgen
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
National Cancer Institute (NCI)
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
M.D. Anderson Cancer Center
More Sotorasib trials
3 international trials (no US sites)
How OncoMatch helps you find Sotorasib trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every Sotorasib trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.